Risdiplam
CAS No. : 1825352-65-5
(Synonyms: RG7916; RO7034067)
| Size | Price | Stock |
|---|---|---|
| 5mg | $165 | In-stock |
| 10mg | $275 | In-stock |
| 25mg | $495 | In-stock |
| 50mg | $935 | In-stock |
| 100mg | $1485 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-109101 |
| M.Wt: | 401.46 |
| Formula: | C22H23N7O |
| Purity: | >98 % |
| Solubility: | Ethanol : < 1 mg/mL;H2O : < 0.1 mg/mL;DMSO : 1.96 mg/mL (ultrasonic;warming;adjust pH to 5 with HCl;heat to 60°C) |
Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels[1]. IC50 & Target:SMN2 In Vitro:Risdiplam modulates SMN2 pre-mRNA splicing towards the production of full-length SMN2 mRNA and increases SMN protein levels. Risdiplam is a modifier of SMN2 splicing, leading to an increase in SMN2 full length transcript and thus functional SMN protein. Spinal muscular atrophy (SMA) type I remains the most common genetic disease resulting in death in infancy. Characterized by progressive motor and respiratory muscle weakness, this autosomal recessive neuromuscular disorder is caused by low levels of the survival motor neuron protein (SMN) due to inactivating bi-allelic deletions and other disabling mutations in the survival motor neuron 1 (SMN1) gene[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Risdiplam
- Cat. No.:
- HY-109101
- Quantity:
Your information is safe with us.